home / stock / khtrf / khtrf news

KHTRF News and Press, Knight Therapeutics Inc From 10/30/25

Stock Information
Company Name: Knight Therapeutics Inc
Stock Symbol: KHTRF
Market: OTC
Website: gud-knight.com
Menu
KHTRF KHTRF Quote KHTRF Short KHTRF News KHTRF Articles KHTRF Message Board
Get KHTRF Alerts

News, Short Squeeze, Breakout and More Instantly...
KHTRF - Knight Therapeutics announces launch of JORNAY PM

2025-10-30 17:39:17 ET More on Knight Therapeutics Inc. Knight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Knight Therapeutics Inc. Historical earnings data for Knight Therapeutics Inc. Financial informati...
KHTRF - Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM™ is an extended-release...

KHTRF - Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial results on Thursday, November 6, 2025 prior to market opening. Following the release, K...

KHTRF - Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina...
KHTRF - Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE ® (relugolix/estradiol/norethindrone acetate) in Canada. In June 2024, ...

KHTRF - Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX ® (relugolix) in Canada. In June 2024, Knight and Sumitomo Pharma America Inc. (“...

KHTRF - Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine’s ranking of Canada’s Top Growing Companies. Canada’...
KHTRF - Knight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Call Transcript

2025-08-08 01:23:30 ET Knight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Conference Call August 07, 2025, 8:30 AM ET Company Participants Amal Khouri - Chief Business Officer Arvind Utchanah - Chief Financial Officer Samira Sakhia - President, CEO & Director ...

KHTRF - Knight Therapeutics Reports Second Quarter 2025 Results

Achieved record-high quarterly revenues since inception Increased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today rep...

KHTRF - Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for ...
Previous 10 Next 10